Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
$1.21 → $1.18 · observed estimates
Escalade, Inc. (ESCA)
NASDAQConsumer DiscretionaryLeisureSnapshot 2026-11-04
$20.39-3.50%
Close 2026-11-05 · 1-day change
NASDAQConsumer DiscretionaryLeisureSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ESCA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Quarterly dividend per share at least $0.15 | Escalade pays a steady quarterly dividend of $0.1525 per share. | Intact | quarterly dividend falls below $0.15 per share | Dividend per share: $0.15 per share FY2026-Q3; GAAP. Published target: >= $0.15 per share quarterly. The stored target says 2026-Q4; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Oct 29, 20260.1525 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
$1.21 → $1.18 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ESCA is a smaller-cap business with a growth-and-margin improvement thesis, rather than a clear turnaround. The multi-year view is intact, though the latest earnings left the signal only mildly favorable and management’s progress on sales growth remains mixed.
The valuation evidence describes ESCA as cheap versus peers, with a lower valuation reading after fresh earnings and no signs of concentrated fragility. The expectations gap is negative, so the evidence does not point to demanding market expectations; confidence in that assessment is high.
Near term, recent results are strong overall, but quarterly revenue was mixed and earnings surprises have been erratic. Gross margin improved, while debt fell and the company reported net cash; some recent margin gains reflected tariff recoveries and favorable mix. A guidance cut on the next call is a meaningful risk.
Over the next few quarters, the thesis hinges on whether management can turn its repeated sales-growth priority into steadier results while sustaining margin gains. Sector bellwethers’ earnings and guidance may also shape the near-term backdrop: continued strength would support momentum, while weakness could remove that tailwind.
For the next 1 to 3 years, the long-term thesis is intact, with strong recent performance and balance-sheet progress offset by uneven growth and elevated risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Escalade pays a steady quarterly dividend of $0.1525 per share. |
| Intact |
| EPS falls below $1.08 in FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue decline limited to no worse than -6% YoY | A primary condition in Escalade, Inc.'s published investment case. The stated target is >= -6% YoY revenue growth. | Intact | revenue decline exceeds -6% YoY in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.25B → $0.25B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-14 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-15 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-16 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-17 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-18 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-19 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-20 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-21 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-22 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-23 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-24 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-25 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-26 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-27 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-28 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-29 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-30 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-10-31 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-11-01 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-11-02 | $1.21 | $253,200,000 | 1 / 1 |
| 2026-11-03 | $1.18 | $251,200,000 | 1 / 2 |
| 2026-11-04 | $1.18 | $251,178,500 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.